Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

J App Pharm Sci. 2022; 12(5): 98-103


Promising chitosan - alginate combination for rifampicin dry powder inhaler to target active and latent tuberculosis

Kurnia Sari Setio Putri, Laily Syahri Ramadhani, Theodora Rachel, Gatot Suhariyono, Silvia Surini.




Abstract
Cited by 2 Articles

Suitable excipient with certain characteristics is required in formulating dry powder inhaler (DPI), to deliver anti-TB drug into the lung and provide adequate drug concentration in the lung and in the alveolar macrophage, to overcome active and latent tuberculosis infection. This study aimed to explore combination of chitosan and alginate in formulating rifampicin DPI. Rifampicin DPI was prepared by spray drying using various combination of chitosan and alginate. The obtained rifampicin dry powder was characterized for its particle size distribution, morphology, moisture content, drug content, and entrapment efficiency. In addition to the dissolution study in phosphate buffer pH 7.4 with SLS 0.05% and in phthalate buffer pH 4.5, the cytotoxicity study towards cell line A549 was also conducted. Combination of chitosan and alginate in DPI F3 (RIF-Ch-Alg 2:1:1) provide suitable drug release profile of rifampicin DPI in both simulated lung fluid (78.301 ± 1.332 % in 2 hours) and in simulated macrophage fluid (41.355 ± 1.259% in 2 hours). DPI F3 also possessed aerodynamic particle size of 11.4288 ± 1.259 µm, and was also considered as safe toward pulmonary epithelial cells (viability 89.73%) in concentration up to 0.1 mg/mL. It is potential to further explore its efficiency in targeting active and latent tuberculosis in vivo.

Key words: rifampicin, dry powder inhaler, chitosan, alginate, drug release profile, cytotoxicity






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.